問卷

TPIDB > Search Result

Search Result

篩選

List

110Cases

2025-02-03 - 2029-12-23

Not yet recruiting
A phase 3 randomized, double-blind, placebo-controlled trial compared TPST-1120 with Atezolizumab plus Bevacizumab to placebo plus Atezolizumab plus Bevacizumab in patients with unresectable or metastatic hepatocellular carcinoma (HCC) who had not received systemic therapy.
  • Condition/Disease

    ● Overall survival (OS) is defined as the time elapsed from random assignment until death from any cause.

  • Test Drug

    TPST-1120

Participate Sites
6Sites

Recruiting6Sites

2025-10-01 - 2029-12-31

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Condition/Disease

    Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    注射劑 皮下注射劑 注射劑 注射劑 注射劑

Participate Sites
7Sites

Recruiting7Sites

2025-11-14 - 2029-06-30

Phase I

Not yet recruiting
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors
  • Condition/Disease

    NSCLC Adenocarcinoma

  • Test Drug

    錠劑 膠囊劑 錠劑

Participate Sites
4Sites

Recruiting4Sites

2023-09-01 - 2033-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting2Sites

Terminated2Sites

2023-09-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-09-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-09-01 - 2027-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2021-04-01 - 2033-02-28

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites